RNA Integrity Number Below 7: Can I Still Trust My qPCR Results?

Short answer: yes, often you can — but it depends on your amplicon size, your targets, and whether the degradation is consistent across your samples. A RIN of 5-6 with short amplicons (< 150 bp) and stable reference genes will usually give you reliable ΔΔCt results. A RIN of 5 in your treated group and a RIN of 9 in your control group is a real problem, and no amount of normalization will fix it.

The "RIN must be ≥ 7" rule comes from microarray and RNA-seq best practices, where you're measuring thousands of transcripts of varying lengths and the entire integrity profile matters. qPCR is more forgiving because you're amplifying short, specific sequences. That said, degradation does affect your data — it shifts Ct values, can differentially impact long vs. short transcripts, and can make your reference genes lie to you. The question isn't whether degradation matters. It's whether it matters enough to change your conclusions.

What RIN Actually Tells You (and What It Doesn't)

The RNA Integrity Number is an algorithm-derived score (1-10) from the Agilent Bioanalyzer or TapeStation electropherogram. It's primarily based on the ratio of 28S to 18S ribosomal RNA peaks and the presence of degradation products between them. A RIN of 10 is pristine total RNA with sharp 18S and 28S peaks. A RIN of 3 looks like a smear of small fragments with no discernible ribosomal peaks.

Here's what RIN doesn't tell you: the integrity of your specific mRNA target. RIN reflects global RNA quality, dominated by the abundant ribosomal species. Your 1.2 kb mRNA of interest might be more or less susceptible to degradation than the rRNA that drives the score. Highly structured transcripts and short mRNAs survive degradation better than long, AU-rich ones. So a RIN of 6 might mean your 800 bp transcript is partially degraded while your 400 bp transcript is essentially fine.

This is why a blanket RIN cutoff is too blunt. What you actually need to evaluate is whether degradation is biasing your comparison between groups.

When Low RIN Will Wreck Your Data

There are three scenarios where RIN < 7 genuinely undermines qPCR results:

1. Uneven degradation across experimental groups. This is the big one. If your FFPE tumor samples sit at RIN 3-4 and your matched normal tissue (fresh-frozen) comes in at RIN 8-9, you have a systematic confound. Degraded samples will show higher Ct values for your GOI, but the magnitude of the shift depends on amplicon length and target abundance. Your reference gene will also shift, but not necessarily by the same amount. The result: artifactual fold changes that reflect degradation, not biology. If your RINs differ by more than ~2 units between groups, be very cautious.

2. Long amplicons. If your primers produce a 250-300 bp product, degraded RNA will disproportionately reduce the number of intact templates available for reverse transcription. With an amplicon of 80-100 bp, most partially degraded molecules still contain the intact target region. This is one reason qPCR primer design guidelines recommend amplicons of 70-150 bp — it's not just about PCR efficiency, it's about tolerance to degradation.

3. Low-abundance targets. When you're already at Ct 32-35 with good RNA, further template loss from degradation can push you into the noise floor. A 1-2 Ct shift from degradation might be tolerable for an abundant target (Ct 18 → 20), but for a rare transcript, it can mean the difference between a detectable signal and an ambiguous late-cycle amplification that's indistinguishable from primer-dimer.

When Low RIN Is Probably Fine

The most common scenario where RIN < 7 is workable: all your samples have similarly low RIN (within ~1.5 units of each other), your amplicons are short, and your reference genes behave consistently.

Here's a practical check. Look at your reference gene Ct values across all samples. If ACTB or HPRT1 gives you Ct values of 18-20 with a standard deviation of < 1 Ct across samples with RINs of 5-7, your normalization is holding up. If the reference gene Ct correlates with RIN (lower RIN → higher Ct, in a dose-dependent pattern), that's a warning sign — your normalization gene is degradation-sensitive and your ΔCt values will be biased.

Some specific situations where RIN < 7 is expected and manageable:

• FFPE tissue. You'll rarely see RIN above 4. The field has largely accepted this and adapted — use short amplicons (< 100 bp), higher RNA input (500 ng-1 µg for RT), and FFPE-validated extraction kits (e.g., Qiagen RNeasy FFPE, Promega Maxwell). Millions of published data points from FFPE qPCR exist with RINs of 2-4.
• Clinical samples with unavoidable processing delays. Blood collected in PAXgene tubes vs. plain EDTA tubes, tissue biopsies that sat in saline for 30 minutes. You work with what you get.
• Sorted cell populations. Flow sorting can take hours, and RNA degrades during the process. RINs of 5-6 are common from sorted cells and generally give reliable qPCR data with short amplicons.

Practical Steps to Validate Your Data With Low-RIN Samples

If you're staring at RINs of 4-6 and need to decide whether to proceed, here's what I'd do:

1. Check RIN distribution across groups. Plot RIN vs. experimental condition. If the means don't differ significantly, you're in reasonable shape. If they do, consider whether the RIN difference could explain your expression differences (and in which direction).

2. Test 2-3 reference genes. Don't rely on a single reference gene when RNA quality is variable. Run ACTB, HPRT1, and B2M (or whatever's appropriate for your tissue). If they all give consistent ΔCt values relative to each other, normalization is working. If one reference gene shows RIN-dependent drift while others don't, drop it. The geNorm algorithm (Vandesompele et al., 2002) is designed for exactly this — identifying the most stable normalizers across your sample set.

3. Plot Ct vs. RIN for your reference gene. A flat line is ideal. A negative correlation (higher RIN → lower Ct) with an R² > 0.3 means degradation is influencing your measurements. You can sometimes include RIN as a covariate in your statistical model, but this is a band-aid — it assumes a linear relationship that may not hold.

4. Run a degradation test. Take one high-quality RNA sample (RIN > 8) and deliberately degrade it: incubate aliquots at 65°C for 0, 15, 30, and 60 minutes. Run your qPCR assay on each. This gives you a direct readout of how sensitive your specific primer/target combination is to degradation. If Ct shifts less than 1 cycle between RIN 8 and RIN 5 equivalents, your assay is robust.

5. Keep amplicons short. If you haven't ordered primers yet and you know your RNA quality will be marginal, design amplicons of 70-100 bp. This single decision buys you more degradation tolerance than anything else.

The Math: How Much Does Degradation Shift Your Fold Change?

Let's work through a concrete example. Suppose degradation causes a 1 Ct increase in both your GOI and your reference gene. Your ΔCt (GOI – REF) is unchanged, and your fold change is unaffected. This is the best case — uniform degradation that your normalization absorbs completely.

Now suppose degradation causes a 1.5 Ct shift in your GOI (longer amplicon, 200 bp) but only a 0.5 Ct shift in your reference gene (shorter amplicon, 90 bp). Your ΔCt shifts by 1.0 Ct, which translates to a 2-fold artifactual change (2¹ = 2). If your biological effect is 8-fold, a 2-fold artifact is unlikely to flip your conclusion. If your biological effect is 1.5-fold, you can no longer distinguish biology from degradation artifact.

This is why the combination of short amplicons for both target and reference and matched degradation across groups matters. Either one alone reduces the risk; both together make low-RIN qPCR quite reliable.

When to Re-Extract or Re-Collect

Sometimes the answer is that you need better RNA, and it's worth being honest about that. Re-extract or re-collect if:

• RIN is below 3 for non-FFPE samples (something went wrong — RNase contamination, thaw-refreeze cycles, bad extraction).
• RIN varies by more than 3 units between groups and you can't justify it biologically.
• Your reference gene Ct values show > 2 Ct spread that tracks with RIN.
• You're trying to measure fold changes < 2 between groups with variable degradation.

If re-collection isn't possible (clinical samples, rare tissue), document the RIN values, show the reference gene stability data, and present the results with appropriate caveats. Reviewers and readers can evaluate the evidence if you're transparent about the limitations.

Reporting RIN in Your Paper

Always report individual RIN values (or at minimum, range and mean ± SD per group) in your methods or supplementary data. State your amplicon sizes. If RINs are below the conventional threshold, briefly explain why your data are still interpretable — reference gene stability, matched degradation, short amplicons. Reviewers will often flag low RIN reflexively; having this information preemptively in the manuscript saves a round of revision.

If you're analyzing qPCR data from samples with variable RIN, VoilaPCR can flag reference gene instability and outlier samples automatically, so you can catch normalization problems before they become figure panels you have to retract.

RNA quality matters, but the RIN ≥ 7 cutoff is a guideline, not a law of thermodynamics. Match your assay design to your sample reality, validate your normalization, and let the data tell you whether degradation is a problem — not an arbitrary threshold.